Key Stats for SYK Stock
- Past week performance: +0.9%
- 52-week range: $281 to $397
- Valuation model target price: $418
- Implied upside: 26.5% over 2.3 years
See Stryker’s recovery timeline modeled out with TIKR’s Guided Valuation Model (It’s free) >>>
Recovering Ground, One Quarter at a Time
Stryker (SYK) is proving that a March cyberattack was a speed bump, not a derailment. Q2 organic sales grew 9%, and adjusted earnings per share rose 18% to $3.69, both ahead of Wall Street estimates. Revenue reached $6.6 billion, up 9.4% year over year, as the company worked through a backlog built up during the outage.
CEO Kevin Lobo said the company “made significant progress in our recovery from the cyber incident.” MedSurg and Neurotechnology organic sales rose 9.2%, and Orthopaedics grew 8.6%, with the Mako robotic-assisted surgery platform posting record quarterly installations across U.S. and international markets. Mako uses robotics and real-time imaging to help surgeons place joint implants more precisely.
Management still narrowed full-year guidance to 8.3% to 9.3% organic sales growth and $14.95 to $15.10 in adjusted earnings per share, citing lingering supply constraints tied to its Inari Medical business and elevated recovery costs. That narrower range disappointed some analysts even though both the top and bottom lines beat estimates.
Director Ronda Stryker sold about $1.14 million in shares on August 21, consistent with routine, pre-planned selling. If SYK stock keeps closing the production backlog through the second half, the narrowed guidance could prove conservative rather than a red flag.
See analysts’ growth forecasts and price targets for SYK (It’s free) >>>
A Recovery Story Priced for Patience
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue Growth (CAGR): 8.4%
- Operating Margins: 27.5%
- Exit P/E Multiple: 20.6x
Based on these assumptions, the model estimates a target price of $418, implying a 26.5% total return from the current share price and a 10.5% annualized return over the next 2.3 years.
Stryker’s valuation looks reasonable rather than cheap, and that fits a medtech company still finishing a cyberattack recovery. Modeled revenue growth of 8.4% sits below the 9% to 9.4% pace the company has actually delivered, suggesting some conservatism baked into the forecast. Operating margins of 27.5% would mark an improvement from today’s level, reflecting expected leverage as supply issues fade.
Compared with Medtronic, which guides for 6.75% to 7.25% organic revenue growth in its new fiscal year, Stryker’s modeled growth still comes in faster despite the recent disruption. Zimmer Biomet, meanwhile, guides for just 2.25% to 3.25% organic growth in 2026, less than half Stryker’s pace, highlighting how much share Stryker has taken in joint replacement and surgical technology.
The 20.6x exit multiple assumed in the model sits close to Stryker’s own long-term average, rather than demanding a premium re-rating. That makes the path to the $418 target depend mostly on execution, closing the order backlog and sustaining Mako’s momentum, rather than on the market suddenly paying up for the stock.
Compare Stryker’s growth against Medtronic and Zimmer Biomet (Free with TIKR) >>>
Stryker Is Outgrowing the Rest of Medtech
Stryker’s growth advantage over its largest peers has only widened since the cyberattack. Medtronic (MDT) just guided to 6.75% to 7.25% organic revenue growth for its new fiscal year, its best outlook in a decade, yet it still trails Stryker’s 9% organic growth from the most recent quarter.
Zimmer Biomet (ZBH) trails by an even wider margin. The company raised its 2026 organic revenue growth guidance to just 2.25% to 3.25% after a Q2 that came in at 4.0% organic growth, while it works through a multi-year overhaul of its U.S. sales force. That gap helps explain why Stryker continues to command a premium valuation within orthopedics and surgical technology.
Stryker’s Mako robotic platform is a key differentiator neither Medtronic nor Zimmer Biomet has fully matched at scale. Record quarterly installations during the same quarter as a major cyberattack recovery suggest underlying demand for Stryker’s technology remains intact even when execution gets disrupted.
What’s Driving SYK Stock Going Forward?
Stryker’s near-term path depends on finishing what management calls a manageable order backlog by the end of the third quarter. Clearing that backlog should let reported growth catch up to underlying demand, which Lobo has described as unchanged since before the cyberattack.
Regulatory news is another swing factor. Proposed Medicare reimbursement cuts for large joint replacements resurface most years, and management expects the usual pattern of industry pushback followed by a more moderate final rule. A continued shift of procedures toward ambulatory surgery centers should keep supporting demand regardless of that process.
Mako RPS, a newer version of the robotic platform aimed at ambulatory surgery centers, is entering a fuller launch after a positive limited rollout. If it ramps as management expects, it could open a new growth channel among surgeons not previously ready for the full Mako system, adding another leg to Stryker’s story heading into 2027.
Track Stryker’s backlog recovery against its own guidance (Free with TIKR) >>>
Should You Invest in Stryker?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up SYK, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track SYK alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze SYK stock on TIKR Free→
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
